✦ LIBER ✦

In Praise of Workby Fr. Raoul Plus

✍ Scribed by Review by: L. Browne

Book ID: 125180209
Year: 1953
Weight: 146 KB
Volume: 81
Category: Article
ISSN: 2009-2113
DOI: 10.2307/20516504

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Peters Plus Syndrome Is Caused by Mutati

Peters Plus Syndrome Is Caused by Mutations in B3GALTL, a Putative Glycosyltransferase

✍ Saskia A.J. Lesnik Oberstein; Marjolein Kriek; Stefan J. White; Margot E. Kalf; 📂 Article 📅 2006 🏛 American Society of Human Genetics 🌐 English ⚖ 255 KB

Phase II randomised trial of chemoradiot

Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer

✍ Conroy, T; Yataghène, Y; Etienne, P L; Michel, P; Senellart, H; Raoul, J L; Mine 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 344 KB

3001 ORAL CRYSTAL, a randomized phase II

3001 ORAL CRYSTAL, a randomized phase III trial of cetuximab plus FOLFIRI vs. FOLFIRI in first-line metastatic colorectal cancer (mCRC)

✍ E. van Cutsem; G. Bodoky; J. Kyung Roh; G. Folprecht; Y.S. Park; J.L. van Laethe 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Histoire de la langue grecqueby Jean Hum

Histoire de la langue grecqueby Jean Humbert;Phonologie du grec attiqueby Liana Lupaş;Greek. A Survey of Recent Workby Fred W. Householder; Gregory Nagy;Prolegomena to a Study of the Greek Language in the First Centuries A.D. The Problem of Koiné and Atticismby Jaakko Frösén

✍ Review by: Alain Pierrot 📂 Article 📅 1978 🏛 Presses Universitaires de France 🌐 French ⚖ 266 KB

289 Phase II study of cetuximab combined

289 Phase II study of cetuximab combined with FOLFIRI (bi-weekly irinotecan plus infusional 5-FU and folinic acid (FA) in patients (pts) with metastatic, Epidermal growth factor receptor (EGFR)-expressing colorectal cancer (CRC)

✍ J.L. Raoul; J.L. van Laethem; E. Mitry; C. Brezault; F. Husseini; L. Cals; M. Pe 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 170 KB

Double-blinded randomized study of high-

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT investigators: Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW, ASCENT Investigators, Division of Hematology and Medical Oncology, Department of Medicine, Oregon Health and Science University, Portland, OR

✍ Donald L. Trump 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 42 KB